Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 1152-1154

  Tantisiriwat, Woraphot ^a   Tebas, Pablo ^a   Clifford, David B ^a   Powderly, William G ^a   Fichtenbaum, Carl J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; DIPLOPIA; DISEASE ASSOCIATION; DYSARTHRIA; GRAND MAL SEIZURE; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; JC VIRUS; LYMPHOCYTE COUNT; MALE; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VISUAL IMPAIRMENT;

EID: 0032938655     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514762     Document Type: Article

References (10)

1. 1. Demeter LM, JC, BK, and other polyomaviruses; progressive multifocal leukoencephalopathy. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:1400-4.
2. 2. Cinque P, Casari S. Progressive multifocal leukoencephalopathy, HIV, and highly active antiretrovinil therapy [letter]. N Engl J Med 1998; 339:848-9.
3. 3. Albrecht H, Hoffmann C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998; 12: 1149-54.
4. 4. Clifford DB. Natural history of progressive multifocal leukoencephalopathy (PML) in AIDS modified by antiretroviral therapy [abstract]. Proceedings of the Neuroscience of HIV Infection Meeting. J Neurovirol 1998; 4:346.
5. 5. Gasnault J, Taoufik Y, Kousignian P, Goujard C, Dussaix E, Delfraissy JF. Effects of protease inhibitors on neurological course in AIDS-progressive multifocal leukoencephalopathy [abstract]. Proceedings of the Neuroscience of HIV Infection Meeting. J Neurovirol 1998; 4:351.
6. 6. Teofilo E, Gouveia J, Brostas V, et al. Progressive multifocal leukoencephalopathy regression with highly active antiretroviral therapy [letter]. AIDS 1998; 12:449.
7. 7. Domingo EB, Guardiola JM, Iranzo A, et al. Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy. Lancet 1997; 349:1554-5.
8. 8. Elliot B, Aromin I, Gold R, et al. 2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy [letter]. Lancet 1997; 349:850.
9. 9. Piliero PJ, Nguyen AD, Reif M. Fatal progressive multifocal leukoencephalopathy (PML) despite highly active antiretroviral therapy (HAART), interferon-alpha2b (TFN-α-2b), and peptide T [abstract no 466]. In: Program and abstracts of the 5th National Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
10. 10. Currier JS, Williams PL, Grimes JM, Squires KS, Fischl M, Hammer SM. Incidence rates and risk factors for opportunistic infections in a phase III trial comparing indinavir + ZDV + 3TC to ZDV + 3TC [abstract no 257]. In: Program and abstracts of the 5th National Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.